YpT1-2N0 rectal cancer after neoadjuvant chemoradiation has lower survival compared with pT1-2N0 rectal cancer

Oncotarget. 2015 Dec 1;6(38):41056-62. doi: 10.18632/oncotarget.5379.

Abstract

Pathologic T1-2N0 rectal cancer shows an excellent prognosis without preoperative or postoperative chemoradiation. However, oncologic outcome of ypT1-2N0 remains unclear and undetermined. Thus, the aim of this study was to compare the survival of ypT1-2 and pT1-2 rectal cancer patients after radical resection and identify risk factors of ypT1-2 rectal cancer in Surveillance, Epidemiology, and End Results Program (SEER)-registered rectal cancer patients. The results showed that ypT1-2N0 rectal cancer after neoadjuvant chemoradiation has lower survival compared with pT1-2N0 rectal cancer and mucinous/signet-ring cancer and less than 12 lymph nodes retrieval were two risk factors in ypT1-2 patients. These results suggest that ypT1-2 patients with one or two risk factors may benefit from postoperative adjuvant chemotherapy.

Keywords: SEER; adjuvant chemotherapy; good response; rectal cancer; risk factors.

Publication types

  • Comparative Study

MeSH terms

  • Chemoradiotherapy, Adjuvant
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Prognosis
  • Proportional Hazards Models
  • Rectal Neoplasms / pathology
  • Rectal Neoplasms / surgery
  • Rectal Neoplasms / therapy*
  • Retrospective Studies
  • Risk Assessment / methods
  • Risk Assessment / statistics & numerical data
  • Risk Factors
  • SEER Program / statistics & numerical data*
  • United States